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the irreversible model. The expression levels of the genes be-
longing to the cluster were low in normal kidney and increased
along with disease peaked at day 14, and the up-regulation was
more pronounced in the irreversible model than the reversible
model. This cluster included collagen type1, laminin, osteopon-
tin, kidney injury molecule-1 (KIM-1), and thymosin b10. These
molecules can be new therapeutic targets for slowing the pro-
gression of renal diseases or accelerating repair of the injured
kidney.
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Epithelial-mesenchymal transition (EMT) is a process
whereby epithelial cell layers lose polarity and cell-cell contacts
and undergo a massive cytoskeleton reorganization involving
the rho family and the remodeling of the actin microfilament
mesh (Thiery, 2002). Concurrent with a loss of epithelial cell
adhesion and cytoskeletal components, cells undergoing EMT
acquire expression of mesenchymal components and manifest
a migratory phenotype. This is a fundamental process govern-
ing morphogenesis in multicellular organisms during embryonic
development. This EMT process, first appreciated by develop-
mental biologists in the early 1980s, is now attracting increasing
attention from oncologists and nephrologists, because the pro-
cess is also reactivated in a variety of diseases, including fibrosis
and in the progression of carcinoma. From a therapeutic stand-
point, it may be important to reverse EMT in these diseases.
EMT is characterized by coordinated changes in cell mor-
phology, associated with the induction of cell motility and the
disruption of intercellular junctions. In some cases, cells under-
going EMT start synthesizing extracellular matrix molecules
such as fibronectin and certain types of collagen. They may also
synthesize proteolytic enzymes involved in matrix degradation
that contribute to cell motility and invasiveness. It should be
stressed that not all EMTs exhibit the whole range of changes
listed here. However, EMT is always associated with cell scat-
tering, defined by the loss of intercellular junctions and acqui-
sition of cell motility. The transformation of mesenchyme to
epithelium (MET), the reverse of EMT, also occurs during em-
bryonic development. The differentiation of the metanephric
blastema provides a striking example of MET. The cardinal
feature of kidney development is the formation of epithelial
tubules from nonepithelial mesenchymal cells. This conversion
of cell type, MET, is controlled by factors secreted from the
ureteric bud (Barasch, 1999; Plisov, 2001), and these epithe-
lial inducers have been purified from ureteric bud cell lines
(Barasch, 1996). These molecules are endogeneous MET induc-
ers. We have tested some of these [bone morphogenetic protein
7(BMP-7) and lipocalin 2] for their epithelial inducing activities
in the context of tumor biology and fibrosis and these results
with potential therapeutic applications have been discussed.
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MUC20, a novel mucin protein highly expressed in kidney,
was isolated as an up-regulated gene in renal tissues of pa-
tients with IgA nephropathy (IgAN) (J Biol Chem 279:1968,
2004). Functional analyses of MUC20 have demonstrated its
role as a negative regulator of hepatocyte growth factor (HGF)–
induced Grb2-Ras pathway. The C-terminus of MUC20 asso-
ciates with the multifunctional docking site of Met, preventing
Grb2 recruitment to Met and thus attenuating HGF-induced
proliferation and matrix metalloproteinase expression (Mol
Cell Biol 24:7456, 2004). In addition, it has been suggested that
the oligomerization of MUC20, caused by its overproduction or
some other unknown factor(s), which leads to this association
with Met. Interestingly, in human MUC20, the repeat numbers
of the extracellular tandem domain, which may have an influ-
ence on the oligomerization, showed a divergence, with two to
six repeat types in several human cell lines. In this study, to
clarify the role of MUC20 in human kidney diseases, we ana-
lyzed the expression of MUC20 in kidney tissues of patients with
IgAN by in situ hybridization. We also investigated the possible
association of the tandem repeat polymorphism of MUC20 with
renal survival in 236 patients with histologically proven IgAN.
In normal kidneys, the expression of MUC20 was confined to
the distal tubules, where Met was colocalized by immunohsito-
chemistry. In addition, glomerular podocytes and the parietal
epithelial cells lining Bowman’s capsule demonstrated positive
expression of MUC20. In renal tissues of IgAN, up-regulation
of MUC20 expression in proximal tubules, as well as in distal
tubules, was observed. By Kaplan-Meier analysis, the prognosis
of IgAN patients with five or six of tandem repeat of MUC20
(N = 130) was significantly better than those without (N =
106, log-rank, v 2 = 10.51) (P = 0.0012). The tandem repeat
polymorphism of MUC20 was an independent risk factor for
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the progression of renal dysfunction even after adjusting for
other clinical risk factors, including hypertension, urinary pro-
tein excretion of more than 1.0 g/day, and no administration
of renin angiotensin system inhibitors. This study supports the
role of MUC20 in regulating the Met signaling cascade, which is
implicated not only in renal development and maintenance of
kidney functions but also in tubular repair and regeneration un-
der pathological conditions in human glomerulonephritis. The
tandem repeat polymorphism in MUC20, which may directly
affect its oligomerization and binding to Met, is associated with
the renal prognosis of IgAN. Factors that regulate the function
of MUC20 may be useful therapeutic agents for progression of
renal injury.
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The use of animal organs for human transplantation could
potentially alleviate the worldwide critical shortage of donor
organs, and thus has stimulated investigation of novel strate-
gies directed at making xenotransplantation applicable to the
clinic. The latter will likely require overcoming barriers of rejec-
tion through strategies utilizing either immune suppression or
tolerance induction, or a combination of the two. We have pre-
viously reported that vascularized donor thymic tissue grafts,
transplanted either as composite thymokidneys or vascularized
thymic lobe grafts, induced tolerance across fully allogeneic bar-
riers in miniature swine. Recently, we have applied the strat-
egy of vascularized thymic lobe transplantation in a model of
hDAF pig-to-baboon xenotransplantation and demonstrated
that these grafts induced donor-specific unresponsiveness for
up to 2 to 3 months following transplantation, at which time the
grafts were lost from apparent humoral rejection. We have now
extended these studies using cloned a-1,3-galactosyltransferase
(GalT) knockout pigs as donors. We report here our initial ex-
perience in a preclinical model of pig-to-baboon xenotrans-
plantation. This abstract presents clinical data on recipients
of GalT knockout kidneys, especially focusing on four long-
term recipients of GalT knockout kidney plus thymus trans-
plantation in detail. Briefly, these four baboons receiving either
xeno-thymokidneys or vascularized thymic lobe plus kidney
maintained longer than 2 months. Three of four long-term sur-
vivors maintained normal plasma creatinine levels for 56, 68,
and 83 days, respectively, before expiring from unexpected
causes (anesthetic complication during surgery to replace an
infected intravenous catheter (day 68), and myocardial infarc-
tion, possibly drug-induced on days 56 and an arterial catheter
trouble on day 83. Cytotoxic T-lymphocyte assays on day 78
in one long-term acceptor showed that the baboon maintained
anti-allo cytotoxic T-lymphocyte responses but lost antipig cyc-
totoxic T-lymphocyte responses, indicating donor-specific un-
responsiveness. The fourth baboon experienced an apparent
rejection crisis between days 53 and 65, which reversed with
anti-T-cell rejection therapy; subsequently the animal expired
on day 81 from pneumonia. Neither hyperacute nor acceler-
ated acute rejection was observed in any animal. Use of GalT
knockout donors markedly extends the survival of vascularized
thymus plus renal xenografts in baboons. Although the induc-
tion regimen still needs to be modified to reduce complications,
these initial results are encouraging with regard to the poten-
tial of cotransplanting vascularized thymic tissue with organ
xenografts as a means of achieving long-term tolerance across
pig-to-primate barriers.
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The introduction of cyclosporine (CsA) into clinical practice
has resulted in marked improvement in the short-term outcome
of organ transplantation, and 1-year survival of renal allografts
has improved significantly. However, the annual rate of kidney
graft loss caused by chronic allograft nephropathy (CAN) has
remained stable over last decade. CAN may result from peri-
operative ischemia at the time of transplantation. Furthermore,
chronic CsA nephrotoxicity may progress to an irreversible re-
nal lesion characterized by tubular atrophy, striped interstitial
fibrosis, hyalinosis of the afferent arteriole, and progressive re-
nal impairment. Recent report demonstrated the therapeutic
effects of hepatocyte growth factor (HGF) in preventing CAN
using a well-established rat CAN model. They showed that
HGF treatment during the initial 4 weeks after engraftment
